Halozyme Therapeutics, Inc.
HALONASDAQHealthcare● Active
$70.73
$-0.80(-1.12%)
Market Cap$8.4B
P/E Ratio—
52W High$82.22
52W Low$51.06
Halozyme Therapeutics, Inc. (HALO) · Balance Sheet
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HALO · as of 2026-06-10
Financial statements
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.14B | $0.60B | $0.34B | $0.36B | $0.74B |
| Net Receivables | $0.44B | $0.31B | $0.23B | $0.23B | $0.09B |
| Inventory | $0.18B | $0.14B | $0.13B | $0.10B | $0.05B |
| Total Current Assets | $0.83B | $1.09B | $0.75B | $0.74B | $0.93B |
| PP&E Net | $0.08B | $0.08B | $0.07B | $0.08B | $0.01B |
| Goodwill | $0.58B | $0.42B | $0.42B | $0.41B | $0.00B |
| Intangible Assets | $0.98B | $0.40B | $0.47B | $0.55B | $0.00B |
| Total Assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.01B | $0.09B |
| Accounts Payable | $0.02B | $0.01B | $0.01B | $0.02B | $0.00B |
| Total Current Liabilities | $0.18B | $0.14B | $0.11B | $0.13B | $0.12B |
| Long-Term Debt | $2.14B | $1.51B | $1.50B | $1.49B | $0.79B |
| Total Liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $0.91B |
| Stockholders Equity | |||||
| Retained Earnings | $0.05B | $0.36B | $0.09B | $0.14B | ($0.06B) |
| Total Stockholders Equity | $0.05B | $0.36B | $0.08B | $0.17B | $0.20B |
| Total Liab & Equity(computed) | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B |
| Debt Summary | |||||
| Total Debt | $2.14B | $1.51B | $1.50B | $1.51B | $0.88B |
| Net Debt | $2.01B | $1.39B | $1.38B | $1.27B | $0.76B |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Halozyme Therapeutics, Inc. data
About Halozyme Therapeutics, Inc. (HALO) Balance Sheet
Halozyme Therapeutics, Inc. (HALO) balance sheet shows total assets of $2.53B with cash of $0.14B. Total liabilities are $2.48B, total debt $2.14B, and stockholders equity $0.05B.
Frequently asked questions
HALO · 4 questionsHalozyme Therapeutics, Inc. has total debt of $2.14B with net debt of $2.01B.
HALO total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10